On Thursday shares of Avon Products Inc. (NYSE:AVP) closed at $8.99. Company’s sales growth for last 5 years was -2.80% and EPS growth for next 5 years is recorded as 3.80%. Avon Products, Inc. (NYSE:AVP), a leading global beauty company, announced that it has decided to postpone to Fall 2015 its Investor Day that the Company was originally scheduled to host on May 13, 2015. Avon will provide an update on its turnaround progress when it reports first-quarter 2015 financial results on April 30, 2015.
La Jolla Pharmaceutical Co. (NASDAQ:LJPC) in last trading activity moved up 5.64% to close at $24.34. Company weekly performance is 28.31% while its quarterly performance stands at 21.70%. La Jolla Pharmaceutical Co. (NASDAQ:LJPC) is -2.21% away from its 52 week high. On April 22, La Jolla Pharmaceutical Company (NASDAQ:LJPC) announced the addition of four new members to its advisory board for the development of LJPC-401, La Jolla’s novel formulation of hepcidin. The advisory board is composed of internationally renowned clinicians, highly respected academics and key opinion leaders in the fields of gastroenterology, hematology and oncology.
On last trading day W. P. Carey Inc. (NYSE:WPC) fell -0.20% to close at $65.45. Its volatility for the week is 1.05% while volatility for the month is 1.50%. WPC’s sales growth for past 5 years was 31.70% and its EPS growth for past 5 years was 5.60%. W. P. Carey Inc. (NYSE:WPC) monthly performance is -5.38%. On April 20, W. P. Carey Inc. (NYSE:WPC), announced that it has acquired a retail hypermarket and garden center in Bad Fischau, Austria for $25.2 million (€23.4 million).
On Thursday shares of Celgene Corporation (NASDAQ:CELG) closed at $116.09. Company’s sales growth for last 5 years was 23.30% and EPS growth for next 5 years is recorded as 25.46%. Celgene International II Sàrl, a wholly-owned subsidiary of Celgene Corp. (NASDAQ:CELG), Friday said it has entered into a strategic collaboration with MedImmune Limited, a wholly-owned subsidiary of AstraZeneca Plc. (AZN, AZN.L), to develop and commercialize an anti-PD-L1 inhibitor, MEDI4736, for hematologic malignancies.
On last trading day Hampton Roads Bankshares Inc. (NASDAQ:HMPR) fell -2.14% to close at $1.83. Its volatility for the week is 3.88% while volatility for the month is 3.50%. HMPR’s sales growth for past 5 years was -13.50% and its EPS growth for past 5 years was 14.90%. Hampton Roads Bankshares Inc. (NASDAQ:HMPR) monthly performance is 3.98%. On April 16, Hampton Roads Bankshares, Inc. (NASDAQ:HMPR), announced that it intends to seek regulatory approval to merge its subsidiaries BHR (doing business as The Bank of Hampton Roads and Gateway Bank & Trust Company) and Shore Bank later this year into a single bank that will do business under the name Shore Bank. In addition, subject to shareholder approval at its upcoming annual shareholder meeting in June, the Company plans to change its name from Hampton Roads Bankshares to Shore Financial Corporation.